Clinical trial NCT02822131: Phosphate in Blood Pressure Regulation
Official title: The Effect of Dietary Phosphate Intake on Blood Pressure Regulation and Renal Sodium Chloride Excretion in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2016-07-04
Enrollment: 10
Sex: MALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: High dietary phosphate intake in the general population is associated with a higher risk for developing kidney disease and cardiovascular disease with an increased overall mortality. Whereas the effects of high phosphate intake on general health become clearer, almost nothing is known about underlying mechanisms. More recently, the investigators and others found in animal models that FGF23 stimulates the renal NaCl cotransporter NCC, the target of thiazide diuretics, and that increased NCC activity may increase blood pressure. The investigators could also show that increasing dietary phosphate intake in mice, increases FGF23 and NCC activity within 3 days. Thus, the objective of this single-centre observational cross-over study including 20-45 year old healthy male probands is to elucidate the role of dietary phosphate on blood pressure regulation and renal handling of sodium chloride in healthy subjects. Further the impact of dietary phosphate intake on the regulation of phosphaturic hormones and other factors regulation blood pressure will be investigated. In addition, the investigators will examine whether phosphate intake modulates gut microbiome composition. The primary outcome in this study is the change in blood pressure in healthy subjects on low-phosphate diet compared to healthy subjects on high-phosphate diet. In addition, to assess changes in NCC activity as the main mechanism of phosphate-sensitive blood pressure regulation, renal sodium chloride excretion after administration of hydrochlorothiazide will be measured. The secondary outcomes of this study are: changes in renal phosphate, calcium and potassium excretion, changes in phosphate regulation hormones such as 25-OH-Vit. D, 1,25-(OH)2-Vit. D, PTH, FGF23, dopamine in plasma and urine, changes in plasma and urinary aldosterone levels, changes in sodium/chloride-cotransporter NCC and NaPi-IIa assessed from urinary exosomes, and changes in stool phosphate excretion and gut microbiome composition.


Eligibility criteria: Inclusion Criteria:

* 20-45 year old healthy male subjects

Exclusion Criteria:

* - Kidney disease (defined by eGFR \< 90 ml/min or microalbuminuria (\> 30mg/d))
* Diabetes mellitus
* Hypertension (RR \> 140/85 mmHg)
* Hypotension (RR \< 90/60 mmHg)
* any regular medication
* non-Western type diet e.g. vegetarian, vegan etc.
* History of kidney stones
* Allergy to sulphonamides or penicillins
* Hereditary fructose intolerance
* known hypersensitivity or allergy to class of drugs used in this study
* Glaucoma
* Vitamin D deficiency (\< 20 ng/ml)
* Hyper- or Hypoparathyroidism
* Hypo- or hyperaldosteronism
* Participation in any other study

Primary outcomes:
measure: Change in blood pressure
timeFrame: 5 days
measure: Change in renal sodium chloride excretion
timeFrame: 5 days
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Nephrology
state: ZH
Study officials:
References: